Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz‐Containing Antiretroviral Therapy-Reference-Cited by-同舟云学术

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz‐Containing Antiretroviral Therapy

Published:2019-07-05 Issue:4 Volume:106 Page:726-733
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin. Pharmacol. Ther.

Author:

Desta Zeruesenay¹,Gammal Roseann S.²³,Gong Li⁴,Whirl‐Carrillo Michelle⁴,Gaur Aditya H.⁵,Sukasem Chonlaphat⁶⁷,Hockings Jennifer⁸,Myers Alan⁹,Swart Marelize¹,Tyndale Rachel F.¹⁰,Masimirembwa Collen¹¹,Iwuchukwu Otito F.¹²,Chirwa Sanika¹³,Lennox Jeffrey¹⁴,Gaedigk Andrea¹⁵,Klein Teri E.⁴,Haas David W.¹³¹⁶

Affiliation:

1. Department of MedicineDivision of Clinical PharmacologyIndiana University School of Medicine Indianapolis Indiana USA

2. Department of Pharmacy PracticeMassachusetts College of Pharmacy and Health Sciences University School of Pharmacy Boston Massachusetts USA

3. Department of Pharmaceutical SciencesSt. Jude Children's Research Hospital Memphis Tennessee USA

4. Department of Biomedical Data ScienceStanford University Stanford California USA

5. Department of Infectious DiseasesSt. Jude Children's Research Hospital Memphis Tennessee USA

6. Division of Pharmacogenomics and Personalized MedicineFaculty of Medicine Ramathibodi HospitalDepartment of PathologyMahidol University Bangkok Thailand

7. Laboratory for PharmacogenomicsFaculty of Medicine Ramathibodi HospitalSomdech Phra Debaratana Medical Center Bangkok Thailand

8. Department of Pharmacy and Genomic Medicine InstituteCleveland Clinic Cleveland Ohio USA

9. Department of Diagnostic & Biomedical SciencesThe University of Texas Health Sciences Center School of Dentistry Houston Texas USA

10. Centre for Addiction and Mental HealthUniversity of Toronto Toronto Ontario Canada

11. African Institute of Biomedical Science & TechnologyWilkins Hospital Harare Zimbabwe

12. Division of Pharmaceutical SciencesFairleigh Dickinson University School of Pharmacy Florham Park New Jersey USA

13. Department of Internal MedicineMeharry Medical College School of Medicine Nashville Tennessee USA

14. Division of Infectious DiseasesEmory University School of Medicine Atlanta Georgia USA

15. Division of Clinical Pharmacology, Toxicology, & Therapeutic InnovationChildren's Mercy Kansas City Kansas City Missouri USA

16. Departments of Medicine, Pharmacology, Pathology, Microbiology, & ImmunologyVanderbilt University School of Medicine Nashville Tennessee USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.1477

Reference40 articles.

1. Clinical Pharmacogenetics Implementation Consortium (CPIC).CPIC Guideline for Efavirenz based on CYP2B6 genotype. (2018).

2. Aberrant Splicing Caused by Single Nucleotide Polymorphism c.516G>T [Q172H], a Marker of CYP2B6*6, Is Responsible for Decreased Expression and Activity of CYP2B6 in Liver

3. Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevance

4. Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants

5. CYP2B618492T→C Polymorphism Compromises Efavirenz Concentration in Coinfected HIV and Tuberculosis Patients CarryingCYP2B6Haplotype *1/*1

Cited by 140 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Functional significance of CYP2B6 gene rare allelic variants identified in Japanese individuals;Biochemical Pharmacology;2024-11

2. PBPK Modeling of Lamotrigine and Efavirenz during Pregnancy: Implications for Personalized Dosing and Drug-Drug Interaction Management;Pharmaceutics;2024-09-03

3. Weight Gain and Antiretroviral Therapy;Infectious Disease Clinics of North America;2024-09

4. Patterns of pharmacogenetic variation in nine biogeographic groups;Clinical and Translational Science;2024-08-29

5. Genetic Variation in CYP2D6, UGT1A4, SLC6A2 and SLCO1B1 Alters the Pharmacokinetics and Safety of Mirabegron;Pharmaceutics;2024-08-17